You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome
SBC: CELDARA MEDICAL, LLC Topic: RProject Summary Rodent borne viral outbreaks are increasing in both frequency and impactAs weather patterns evolverodent populations are affected and may multiply in areas where increased contact with humans results in infectionHantavirusesincluding AndesANDVand Sin NombreSNVare transmitted through the excreta of infected rodents andwhen aerosolizedinfect humansIn the Americashantavirus infection ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Silica Colloidal Crystals for High Resolution MALDI-MS of Glycoproteins
SBC: LI-COR, Inc. Topic: 100DESCRIPTION provided by applicant The product is a slide coated with silica colloidal crystals to combine protein electrophoresis with matrix assisted laser desorption ionization mass spectrometry MALDI MS detection giving superior performance in both The Phase II proposal will be to develop an instrument for facile application of the slide in proteomics of intat glycoproteins This propos ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
SBC: Immunext, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): The immune system depends upon an exquisite balance between positive and negative signals to maintain proper function. However, disruptions of this balance can lead to inappropriate responses: for example loss of negative regulation can result in autoimmunity. VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation), is a recently identified n ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
A Novel Broad-spectrum Antiviral Agent
SBC: CELDARA MEDICAL, LLC Topic: NIAIDSummary Accelerating emergence and re-emergence of a wide array of viral epidemics has been a deadly feature of the 21st century. Potent or even effective therapies are rarely available to combat these diseases, and in general, the world remains unprepared to manage future outbreaks. The most recent outbreak of the Ebola virus resulted in over 11,000 fatalities, more than 20,000 orphans, and econo ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Response-Selective C5a Agonist for the Treatment of Asthma
SBC: Prommune, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): An unmet need in the treatment of allergic asthma is an effective therapeutic strategy that focuses on an underlying cause of the disease rather than merely treating or managing its symptoms. At least one well- accepted underlying contributor to the pathophysiologic expression of asthma is an over-expressed and dysregulated T helper type 2 (Th2)-mediated immun ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus
SBC: VAXSYNA, INC. Topic: NCIProject Summary. Human papillomavirus (HPV) is a major public health concern due to 1) its implication in cancers of the anus, cervix, oropharynx, penis, vulva, and vagina; 2) global economic burden, and 3) vastly disproportionate impact on low-to-middle-income countries (LMIC). HPV-related cancers are responsible for 4.5% of all new cancer cases worldwide, 90% of HPV-related cervical cancer death ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma
SBC: ADDUCTNE LLC Topic: 102In 2020 alone, pancreatic cancer is estimated to have resulted in 47,050 deaths in the U.S. making it the fourth leading cause of cancer-related death. Pancreatic ductal adenocarcinoma (PDAC) makes up greater than 90% of all pancreatic cancer diagnoses and has an overall five-year survival rate of just 10%. New therapeutic options are needed to improve the poor prognosis for patients with PDAC. Ex ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization
SBC: Breezmed Topic: 104ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer
SBC: ACTORIUS PHARMACEUTICALS, LLC Topic: 100DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health